About Allergan plc
Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Exchange: NYSE
- Symbol: AGN
- CUSIP: 01849010
- Previous Close: $246.25
- 50 Day Moving Average: $230.36
- 200 Day Moving Average: $222.11
- 52-Week Range: $184.50 - $299.11
- Trailing P/E Ratio: 6.41
- Foreward P/E Ratio: 13.77
- P/E Growth: 1.13
- Market Cap: $91.83B
- Outstanding Shares: 375,080,000
- Beta: 1.07
- Net Margins: 100.04%
- Return on Equity: 7.21%
- Return on Assets: 4.00%
Companies Related to Allergan plc:
- Debt-to-Equity Ratio: 0.37%
- Current Ratio: 3.95%
- Quick Ratio: 3.86%
What is Allergan plc's stock symbol?
Allergan plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan plc pay dividends? What is the dividend yield for Allergan plc?
Allergan plc announced a quarterly dividend on Wednesday, November 2nd. Stockholders of record on Tuesday, February 28th will be given a dividend of $0.70 per share on Tuesday, March 28th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.14%. The ex-dividend date is Friday, February 24th. This is a positive change from Allergan plc's previous quarterly dividend of $0.05.
Where is Allergan plc's stock going? Where will Allergan plc's stock price be in 2017?
25 brokerages have issued 12 month price objectives for Allergan plc's shares. Their predictions range from $205.00 to $330.00. On average, they anticipate Allergan plc's share price to reach $274.37 in the next twelve months.
When will Allergan plc announce their earnings?
Allergan plc is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.
What are analysts saying about Allergan plc stock?
Here are some recent quotes from research analysts about Allergan plc stock:
- Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)
According to Zacks Investment Research, "Allergan is reshaping its portfolio through acquisitions/divestitures. Allergan has been pretty active on the acquisition front and made six new product acquisitions in the third quarter. With the Allergan, Inc. acquisition, the company finds itself among the top 10 pharmas worldwide based on sales. Moreover, with the closing of the Teva deal, the company’s restructured and simplified business is encouraging. As a result, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Biosimilars also represent significant opportunity. Also, Allergan’s shares outperformed the generic industry in past six months. However, while we remain optimistic about the company’s growth prospects, the company is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us." (1/3/2017)
Citigroup Inc. analysts commented, "should not be overlooked."Allergan's first-quarter adjusted earnings of $3.04 per share topped the Street's estimate of $3.01. The company's adjusted top line grew 48.1 percent to $3.9 billion, yet came in below consensus view of $3.95 billion. Related Link: Allergan Q1 Adjusted Earnings Beat Predictions"While AGN's 1Q16 revenues missed consensus expectations, we note the strong performance of key brands (Botox, Linzess, Lumigan, Alphagan, dermal fillers) vs. Street expectations," analyst Liav Abraham wrote in a note.Share Buyback ProgramThe Botox maker also authorized a new $10 billion share buyback program, of which $4 billion–$5 billion is expected to be executed over the next four to six months."While the share buyback signals management's view regarding the stock's valuation, it also preserves meaningful optionality for execution on incremental business development opportunities," Abraham noted.A Look ForwardLooking ahead, Allegan still sees adjusted revenues of $17 billion for the current year. That included branded net revenue of $15 billion. The Street analysts expect the company to deliver $16.88 billion revenue. The company indicated that its non-GAAP R&D is expected to be $1.5 billion."While the positive development of a share buyback may be moderated by the 1Q16 top-line miss, we maintain our view regarding the quality of AGN's core assets and the company's growth profile vs. the peer group," (5/11/2016)
Who owns Allergan plc stock?
Allergan plc's stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.75%), Appaloosa LP (1.14%), Janus Capital Management LLC (1.04%), Baupost Group LLC MA (0.92%), Edgewood Management LLC (0.67%) and Dimensional Fund Advisors LP (0.42%). Company insiders that own Allergan plc stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro.
Who sold Allergan plc stock? Who is selling Allergan plc stock?
Allergan plc's stock was sold by a variety of institutional investors in the last quarter, including Thornburg Investment Management Inc., Bain Capital Public Equity Management LLC, State Street Corp, DSM Capital Partners LLC, Institutional Capital LLC, Levin Capital Strategies L.P., Handelsbanken Fonder AB and Bluestein R H & Co..
Who bought Allergan plc stock? Who is buying Allergan plc stock?
Allergan plc's stock was acquired by a variety of institutional investors in the last quarter, including Appaloosa LP, Edgewood Management LLC, Baupost Group LLC MA, Russell Investments Group Ltd., Janus Capital Management LLC, Iridian Asset Management LLC CT, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main and NWQ Investment Management Company LLC. Company insiders that have bought Allergan plc stock in the last two years include Brent L Saunders, Maria Teresa Hilado and Paul Bisaro.
How do I buy Allergan plc stock?
Shares of Allergan plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Allergan plc stock cost?
One share of Allergan plc stock can currently be purchased for approximately $244.82.